vs
Side-by-side financial comparison of CATHAY GENERAL BANCORP (CATY) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $222.8M, roughly 1.3× CATHAY GENERAL BANCORP). CATHAY GENERAL BANCORP runs the higher net margin — 653.4% vs 12.8%, a 640.6% gap on every dollar of revenue. On growth, CATHAY GENERAL BANCORP posted the faster year-over-year revenue change (19.5% vs -6.4%). Over the past eight quarters, CATHAY GENERAL BANCORP's revenue compounded faster (12.8% CAGR vs 4.2%).
Cathay General Bancorp is a U.S.-headquartered bank holding company that operates Cathay Bank, offering full-spectrum commercial and personal banking services. It primarily serves Asian American communities and small-to-medium enterprises across major U.S. states including California, New York and Texas, as well as select Asian markets, with products covering deposits, loans, and wealth management solutions.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CATY vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $222.8M | $295.9M |
| Net Profit | $90.5M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | 50.9% | 18.4% |
| Net Margin | 653.4% | 12.8% |
| Revenue YoY | 19.5% | -6.4% |
| Net Profit YoY | 12.9% | 68.3% |
| EPS (diluted) | $1.33 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $222.8M | $295.9M | ||
| Q3 25 | $210.6M | — | ||
| Q2 25 | $196.6M | $317.0M | ||
| Q1 25 | $187.8M | $316.2M | ||
| Q4 24 | $186.5M | $297.0M | ||
| Q3 24 | $189.5M | $289.5M | ||
| Q2 24 | $178.5M | $306.1M | ||
| Q1 24 | $175.2M | $303.4M |
| Q4 25 | $90.5M | $38.0M | ||
| Q3 25 | $77.7M | — | ||
| Q2 25 | $77.5M | $-17.7M | ||
| Q1 25 | $69.5M | $22.6M | ||
| Q4 24 | $80.2M | $34.9M | ||
| Q3 24 | $67.5M | $33.6M | ||
| Q2 24 | $66.8M | $40.6M | ||
| Q1 24 | $71.4M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | 50.9% | 18.4% | ||
| Q3 25 | 44.5% | — | ||
| Q2 25 | 49.0% | -7.5% | ||
| Q1 25 | 46.1% | 12.2% | ||
| Q4 24 | 46.5% | 16.0% | ||
| Q3 24 | 41.2% | 13.8% | ||
| Q2 24 | 40.7% | 15.0% | ||
| Q1 24 | 45.7% | 22.1% |
| Q4 25 | 653.4% | 12.8% | ||
| Q3 25 | 36.9% | — | ||
| Q2 25 | 39.4% | -5.6% | ||
| Q1 25 | 37.0% | 7.1% | ||
| Q4 24 | 587.9% | 11.7% | ||
| Q3 24 | 35.6% | 11.6% | ||
| Q2 24 | 37.4% | 13.3% | ||
| Q1 24 | 40.8% | 16.2% |
| Q4 25 | $1.33 | $0.24 | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $1.10 | $-0.11 | ||
| Q1 25 | $0.98 | $0.14 | ||
| Q4 24 | $1.11 | $0.22 | ||
| Q3 24 | $0.94 | $0.21 | ||
| Q2 24 | $0.92 | $0.26 | ||
| Q1 24 | $0.98 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | $119.1M | $260.0M |
| Stockholders' EquityBook value | $2.9B | $2.0B |
| Total Assets | $24.2B | $2.5B |
| Debt / EquityLower = less leverage | 0.04× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M | ||
| Q1 24 | — | $145.3M |
| Q4 25 | $119.1M | $260.0M | ||
| Q3 25 | $119.1M | — | ||
| Q2 25 | $119.1M | $346.0M | ||
| Q1 25 | $119.1M | $330.0M | ||
| Q4 24 | $119.1M | $300.0M | ||
| Q3 24 | $119.1M | $300.0M | ||
| Q2 24 | $119.1M | $319.0M | ||
| Q1 24 | $119.1M | $389.0M |
| Q4 25 | $2.9B | $2.0B | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $2.9B | $1.9B | ||
| Q1 25 | $2.9B | $2.0B | ||
| Q4 24 | $2.8B | $2.1B | ||
| Q3 24 | $2.8B | $2.1B | ||
| Q2 24 | $2.8B | $2.1B | ||
| Q1 24 | $2.8B | $2.0B |
| Q4 25 | $24.2B | $2.5B | ||
| Q3 25 | $24.1B | — | ||
| Q2 25 | $23.7B | $2.6B | ||
| Q1 25 | $23.2B | $2.6B | ||
| Q4 24 | $23.1B | $2.7B | ||
| Q3 24 | $23.3B | $2.7B | ||
| Q2 24 | $23.2B | $2.7B | ||
| Q1 24 | $23.4B | $2.7B |
| Q4 25 | 0.04× | 0.13× | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.04× | 0.18× | ||
| Q1 25 | 0.04× | 0.16× | ||
| Q4 24 | 0.04× | 0.14× | ||
| Q3 24 | 0.04× | 0.14× | ||
| Q2 24 | 0.04× | 0.15× | ||
| Q1 24 | 0.04× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $368.6M | — |
| Free Cash FlowOCF − Capex | $363.7M | — |
| FCF MarginFCF / Revenue | 163.2% | — |
| Capex IntensityCapex / Revenue | 2.2% | — |
| Cash ConversionOCF / Net Profit | 4.07× | — |
| TTM Free Cash FlowTrailing 4 quarters | $672.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $368.6M | — | ||
| Q3 25 | $150.6M | — | ||
| Q2 25 | $64.0M | $98.2M | ||
| Q1 25 | $99.0M | $41.1M | ||
| Q4 24 | $329.2M | $84.3M | ||
| Q3 24 | $81.2M | $63.9M | ||
| Q2 24 | $72.9M | $75.5M | ||
| Q1 24 | $88.2M | $81.0M |
| Q4 25 | $363.7M | — | ||
| Q3 25 | $150.1M | — | ||
| Q2 25 | $62.7M | $93.3M | ||
| Q1 25 | $96.3M | $31.0M | ||
| Q4 24 | $325.5M | $77.5M | ||
| Q3 24 | $80.0M | $54.7M | ||
| Q2 24 | $72.4M | $57.5M | ||
| Q1 24 | $87.3M | $64.5M |
| Q4 25 | 163.2% | — | ||
| Q3 25 | 71.3% | — | ||
| Q2 25 | 31.9% | 29.4% | ||
| Q1 25 | 51.2% | 9.8% | ||
| Q4 24 | 174.6% | 26.1% | ||
| Q3 24 | 42.2% | 18.9% | ||
| Q2 24 | 40.5% | 18.8% | ||
| Q1 24 | 49.8% | 21.3% |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.6% | 1.5% | ||
| Q1 25 | 1.4% | 3.2% | ||
| Q4 24 | 1.9% | 2.3% | ||
| Q3 24 | 0.6% | 3.2% | ||
| Q2 24 | 0.3% | 5.9% | ||
| Q1 24 | 0.5% | 5.4% |
| Q4 25 | 4.07× | — | ||
| Q3 25 | 1.94× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 1.42× | 1.82× | ||
| Q4 24 | 4.10× | 2.42× | ||
| Q3 24 | 1.20× | 1.90× | ||
| Q2 24 | 1.09× | 1.86× | ||
| Q1 24 | 1.23× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CATY
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
